Some 24 million people in 128 low- and middle-income countries now have access to HIV treatments that once would have cost tens of thousands of dollars a year, the BBC reports.
According to a press release, a decade-long partnership between UNITAID, ViiV Healthcare, and 15 generic drug makers has produced more than 1 billion packs of dolutegravira drug used to treat HIVfor those in need.
"This means that as 2023, over 90% of people on antiretroviral treatment in these countries are estimated to be on DTG-based treatments," the press release states.
UNITAID estimates that 90% of people living with HIV in these countries will be on DTG by 2023.
The press release states that in South Africa, for instance, three-month-old babies are now receiving DTG treatments for the first time.
"When Unitaid established the Medicines Patent in 2010, we doubted whether licensing was possible," UNITAID's executive director says.
"Thanks to this 10-year partnership, millions of people with HIV now have access to affordable dolutegravir treatments."
A customized collection of grant news from foundations and the federal government from around the Web.
Vertical farms are designed in a way to avoid the pressing issues about growing food crops in drought-and-disease-prone fields miles away from the population centers in which they will be consumed.